Premium
Total Synthesis of Syringolin A and Improvement of Its Biological Activity
Author(s) -
Chiba Takuya,
Hosono Hidetaka,
Nakagawa Koji,
Asaka Masahiro,
Takeda Hiroshi,
Matsuda Akira,
Ichikawa Satoshi
Publication year - 2014
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201402428
Subject(s) - proteasome , chemistry , bortezomib , proteasome inhibitor , protein subunit , substituent , biological activity , inhibitory postsynaptic potential , intramolecular force , total synthesis , stereochemistry , combinatorial chemistry , biochemistry , in vitro , biology , immunology , gene , neuroscience , multiple myeloma
The development process for syringolin A analogues having improved proteasome inhibitory and antitumor activity is described. The strategy was to first establish a convergent synthesis of syringolin A using a rare intramolecular Ugi three‐component reaction in the last stage of the synthesis, so as to gain access toa set of structure‐based analogues. The inhibitory activity of chymotrypsin‐like activity of 20S proteasome was largely improved by targeting the S3 subsite of the β5 subunit. Cytotoxic activity was also improved by installing the membrane‐permeable substituent. These biological properties are comparable to those of bortezomib, a clinically used first‐line proteasome inhibitor.